Should I buy Arrowhead Pharmaceuticals (ARWR) stock or is it too late?
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 70% of its targets hit on this sector (238 calls tested). It aims for $120 (+36 %), call made on August 7, 2026, maturing on August 7, 2027 (21 d ago).
Firm-by-firm track record on Arrowhead Pharmaceuticals
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Cantor Fitzgerald | 62 % | +73.5 % | 8 | $47 -47% |
| Chardan Capital | 42 % | +59.7 % | 19 | $115 +30% |
| HC Wainwright & Co. | 46 % | +57.1 % | 24 | $120 +35% |
| RBC Capital | 42 % | +47.0 % | 12 | $87 -2% |
| B. Riley Securities | 50 % | +42.0 % | 10 | $123 +39% |
| Piper Sandler | 50 % | +38.0 % | 10 | $126 +42% |
✅ Reasons to believe
- 80% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
- Median price target $107, i.e. +20% from the current price ($89).
- The most reliable firm on ARWR, B. Riley Securities (50% hit rate, 10 scored calls), targets $123 (call made on July 30, 2026, maturing on July 30, 2027) (+39%) in its most recent call, and $101 (call made on January 22, 2026, maturing on January 22, 2027) (+14%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 10 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on ARWR
Median target $107 (+20%) · 10 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Arrowhead Pharmaceuticals now?
We won't decide for you. The facts: 80% of analysts rate it a buy, median target $107 (+20%), and B. Riley Securities (most reliable on ARWR, 50%) targets $123. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Arrowhead Pharmaceuticals?
Not according to analysts: the median target ($107) is still +20% above the current price ($89) (most reliable on ARWR: B. Riley Securities, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Arrowhead Pharmaceuticals still worth investing in?
It depends on the gap between the price ($89) and its estimated value: analysts target $107 on median (+20%), with 80% buys (most reliable on ARWR: B. Riley Securities, 50%). Cross-check with their real reliability on ARWR and the cautions above. Information, not advice.
What's the main risk in buying ARWR?
The consensus is not unanimous: of 10 ratings, 2 are neutral.
→ Go deeper: the full Arrowhead Pharmaceuticals profile (consensus, analyst reliability, price target, performance).